Novavax (NVAX) said Wednesday it has agreed to sell its manufacturing facility in Bohumil, Czech Republic, to Novo Nordisk (NVO) for $200 million.
The asset sale includes a 150,000-square-foot recombinant protein manufacturing facility with support buildings.
The consideration for the deal consists of a $190 million cash payment, and a $10 million additional payment in 2025.
The company also expects the deal to reduce its annual operating costs by about $80 million.
The deal is anticipated to close by Dec. 30.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.